Post-earnings recap
Reported
Wed, Nov 10, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that while Soleno Therapeutics managed to beat EPS expectations, the lack of revenue data and no guidance update may raise concerns among investors. The stock's decline of 3.49% suggests that the market is reacting negatively to the uncertainty surrounding the company's future performance and financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +9.09% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about future developments. They emphasized their commitment to advancing their projects despite current challenges.
Management highlighted ongoing efforts to advance their pipeline.
They acknowledged challenges but remain focused on long-term goals.